Pacific Biosciences of California, Inc. - Common Stock (PACB)
1.6300
-0.1100 (-6.32%)
NASDAQ · Last Trade: Nov 13th, 11:16 PM EST
Detailed Quote
Previous Close
1.740
Open
1.720
Bid
1.630
Ask
1.640
Day's Range
1.610 - 1.730
52 Week Range
0.8511 - 2.460
Volume
6,567,610
Market Cap
402.74M
PE Ratio (TTM)
-0.7581
EPS (TTM)
-2.1
Dividend & Yield
N/A (N/A)
1 Month Average Volume
10,727,131
Chart
About Pacific Biosciences of California, Inc. - Common Stock (PACB)
Pacific Biosciences is a biotechnology company that specializes in developing advanced sequencing technologies designed to enable detailed analysis of genetic material. The company's innovative platforms are used for applications such as genomics research, clinical diagnostics, and personalized medicine, providing researchers and healthcare professionals with powerful tools for understanding complex biological systems. Their technology focuses on real-time, high-fidelity sequencing, allowing for the detection of genetic variations that traditional methods may miss, thereby contributing to significant advancements in the fields of genomics and molecular biology. Read More
Shares of genomics company Pacific Biosciences of California (NASDAQ:PACB) fell 7.5% in the afternoon session after the market continued to react negatively to the company's third-quarter financial results, which missed Wall Street expectations. Management pointed to a slowdown in instrument shipments, especially its Vega systems in Europe, and lower average selling prices for its Revio systems as the main reasons for the underperformance. The company's CEO also described the funding environment in the Americas as “challenging,” which made it take longer for some academic and government research customers to make purchases. Adding to investor concerns, the company is not yet profitable and reported a net loss of $38 million in the last quarter.
PacBio’s third quarter was met with a significant negative market reaction, reflecting disappointment over revenue that fell short of Wall Street expectations. Management attributed the underperformance primarily to a slowdown in instrument shipments, especially Vega systems in Europe, and lower average selling prices for Revio systems. CEO Christian Henry highlighted that while instrument placements were weaker, consumable sales reached an all-time high, driven by growing adoption among clinical and commercial customers. Henry described the funding environment in the Americas as “challenging,” particularly for academic and government research customers, which lengthened procurement cycles and weighed on demand.
Shares of genomics company Pacific Biosciences of California (NASDAQ:PACB) jumped 2.8% in the afternoon session after an analyst at Stephens & Co. raised the price target on the stock while maintaining a positive rating. Analyst Mason Carrico boosted the price target for Pacific Biosciences to $2.00 from $1.80, which marked an increase of over 11%. The firm also kept its 'Overweight' rating on the shares. This action signaled continued confidence from the analyst that the stock could perform well relative to others in its sector. The update provided a positive signal for investors, suggesting a more optimistic outlook on the company's valuation.
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at PacBio (NASDAQ:PACB) and the best and worst performers in the life sciences tools & services industry.
Genomics company Pacific Biosciences of California (NASDAQ:PACB) missed Wall Street’s revenue expectations in Q3 CY2025, with sales falling 3.8% year on year to $38.44 million. Its non-GAAP loss of $0.12 per share was 14.2% above analysts’ consensus estimates.
Genomics company Pacific Biosciences of California (NASDAQ:PACB) fell short of the markets revenue expectations in Q3 CY2025, with sales falling 3.8% year on year to $38.44 million. Its non-GAAP loss of $0.12 per share was 14.2% above analysts’ consensus estimates.
Shares of genomics company Pacific Biosciences of California (NASDAQ:PACB) jumped 17.9% in the afternoon session after its positive momentum continued as it was disclosed that Cathie Wood's investment firm, ARK Invest, purchased more than one million of the company's shares. The firm's ARKK fund acquired 1,028,318 shares, a stake valued at approximately $2,025,786. The move from the well-known, innovation-focused investor signaled strong confidence in the genomics company. This purchase was also consistent with ARK's buying pattern of PacBio stock over the preceding week, highlighting the firm's continued positive view of the sector.
Ark Invest made significant trades involving PLTR, AMD, PACB, and DASH. They sold Palantir and bought AMD, Pacific Biosciences, DoorDash, Iridium, Intellia, Deere, and Synopsys.
Shares of genomics company Pacific Biosciences of California (NASDAQ:PACB) jumped 4.4% in the afternoon session after the company received a significant vote of confidence from Cathie Wood's ARK Invest. The well-known investment firm's ARKG exchange-traded fund (ETF) purchased 1,035,568 shares of the biotech company, a transaction valued at $1,905,445. A substantial purchase by a prominent investor like ARK Invest often signals strong belief in a company's technology and future prospects. This move likely encouraged other investors and led to increased buying activity, which pushed the stock price higher during the session.
While some companies burn cash to fuel expansion, others struggle to turn spending into sustainable growth.
A high cash burn rate without a strong balance sheet can leave investors exposed to significant downside.
A number of stocks fell in the afternoon session after worries over worsening trade relations with China were triggered by critical comments from President Donald Trump.
Shares of genomics company Pacific Biosciences of California (NASDAQ:PACB) jumped 5.4% in the afternoon session after the company announced its HiFi sequencing technology was selected as the primary platform for South Korea's national pangenome project. The project, a major national initiative led by the Korea Disease Control and Prevention Agency, aimed to sequence more than 1,000 whole genomes. The goal was to generate high-quality reference genomes specific to the Korean population, which would then be integrated into the global Human Pangenome Reference Consortium. This effort was expected to help researchers discover population-specific genetic variations, leading to better insights into diseases and the development of more precise diagnostics and treatments.Contributing to the positive momentum, the major indices rebounded as signs of easing trade tensions between the U.S. and China emerged over the weekend. The tech-focused Nasdaq Composite jumped around 1.7%, while the S&P 500 gained 1.2%. This rebound follows a significant sell-off the previous trading day, which saw the Nasdaq plummet 3.6% and the S&P 500 sink 2.7% after threats of new tariffs heightened fears of a trade war. Investor sentiment improved after the U.S. President adopted a more conciliatory tone toward Beijing in a social media post. The shift in language helped calm market jitters and spurred a broad-based rally as investors welcomed the potential de-escalation of the trade dispute.
Shares of genomics company Pacific Biosciences of California (NASDAQ:PACB) jumped 9.3% in the morning session after the National Institute on Aging's Long Life Family Study (LLFS) selected its technology to generate comprehensive genomic data.
San Diego, CA – October 1, 2025 – Illumina, Inc. (NASDAQ: ILMN) saw its shares surge by 6.6% today following the announcement and immediate launch of its new business unit, BioInsight. This strategic move marks a significant pivot for the genomic sequencing giant, as it ventures deeper into the burgeoning fields
In a groundbreaking leap for global health security, the Defense Advanced Research Projects Agency (DARPA) officially launched its Network of Optimal Dynamic Energy Signatures (NODES) program in July 2025. This ambitious initiative is poised to fundamentally transform humanity's defense against future pandemics and biowarfare threats by leveraging advanced artificial intelligence
Small-cap stocks can be incredibly lucrative investments because their lack of analyst coverage leads to frequent mispricings.
However, these businesses (and their stock prices) often stay small because their subscale operations make it harder to expand their competitive moats.
Shares of genomics company Pacific Biosciences of California (NASDAQ:PACB) jumped 2% in the pre market session after the stock extended its positive momentum as the company partnered with DKSH and Chulalongkorn University to launch 'LIFE-SEQ', Asia's first genomic program for precision health.
As the Q2 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the life sciences tools & services industry, including PacBio (NASDAQ:PACB) and its peers.
